In its latest quarter ending June 30, 2026, Disc Medicine reported ongoing clinical development activities primarily centered on bitopertin for erythropoietic porphyrias. The company faces regulatory risk following FDA’s refusal to accept accelerated approval based on surrogate endpoints, mandating Phase 3 confirmatory trials. Alongside bitopertin, the biotech maintains a diverse pipeline targeting anemia and myeloproliferative disorders. Despite significant operating losses typical of pre-commercial biotechs, Disc Medicine holds nearly $99 million in cash and equivalents with minimal debt, providing a runway to advance clinical programs.